BioThrust secures pre-seed extension for cell and gene therapy technology

Biotech startup BioThrust has closed a pre-seed extension financing round to advance the further development of its cell and gene therapy technology. The amount of the financing was not disclosed.

The capital will be used in particular for international pilot studies with the aim of demonstrating the industrial scalability of the technology and building a robust data base for commercialization.

High costs slow down breakthrough of cell and gene therapies

Cell and gene therapies are considered to be one of the most promising approaches in modern medicine. At the same time, high production costs and long development cycles have so far prevented broad market penetration.

As a result, therapies remain economically inaccessible for many patients.

Bioreactor platform to make production more efficient

BioThrust is developing "ComfyCell", a bioreactor platform designed to make the production of stem cells more efficient and scalable. According to the company, it has already achieved record-breaking results in stem cell production.

BioThrust now intends to use the new funds to accelerate pilot projects worldwide in order to validate the benefits of the technology under real conditions.

Broad support from investors and network

Existing investors include RWTH Aachen University and Freigeist. New investors include ALAGO, NRW.BANK and Theo Bongartz.

The company is also supported by several business angels, including experts from science and industry.

Focus on commercialization of therapies

With the financing, BioThrust is pursuing the goal of making cell and gene therapies commercially scalable. The planned pilot studies are intended to show how production processes can be made more efficient, thereby significantly reducing the costs per therapy in the long term.